Pharma industry groups and companies set out their aims for US biosimilars legislation at FDA hearing

5 November 2010

Representatives of the pharmaceutical, biotechnology and generic drugs industries spent a couple of days this week at the US Food and Drug Administration headquarters in Rockville, Maryland, to discuss the implementation and regulation of a regulatory pathway for follow-on biologics - or biosimilars - medications.

On March 23, 2010, President Barack Obama signed into law the Patient Protection and Affordable Care Act which contained a provision authorizing the FDA to create an abbreviated approval pathway for biological products shown to be biosimilar to with an already FDA-approved biological medicine. Several countries have already implemented approval pathways for biosimilars. The European Union and Japan are among those that have successfully devised a set of science-based criteria to permit biosimilars in their jurisdictions. With the FDA's hearing on November 2-3, the USA is beginning the implementation process, but a quick resolution is not expected.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology